1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

RP.V
RepliCel Life Sciences Inc.CA flagToronto Stock Exchange Ventures
0.02
CAD
+0.01
- -
1.10MMarket Cap
RepliCel Life Sciences Inc.
RP.V
(Toronto Stock Exchange Ventures)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
0.91
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
0.01
Revenue per Share
-4.96
-1.35
0.63
-1.18
-1.06
-0.79
-0.01
-1.02
-0.89
-0.54
-0.32
-0.13
-0.12
-0.06
-0.13
-0.02
- -
Basic EPS, GAAP
-2.41
-1.12
-1.36
-0.42
-0.9
-0.7
0.11
-0.88
-0.77
-0.45
-0.29
0.02
-0.12
-0.03
-0.08
-0.04
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-75.41
-74.16
-73.52
0.11
-1.97
-2.4
-2.27
-3.04
-3.61
-0.36
-0.25
-0.3
-0.38
-0.36
-0.37
-0.3
-0.21
Book Value per Share
-0.82
-2.15
-1.52
0.32
0.11
- -
0.33
0.35
-0.11
0.15
-0.02
-0.09
-0.18
-0.19
-0.21
-0.16
-0.11
Tangible Book Value per Share
- -
- -
- -
2
3
4
5
5
6
8
19
22
24
27
32
38
58
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
9.3
- -
- -
- -
- -
-1,608.85
-827.41
-375.5
-649.78
-393.71
-387.01
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
- -
- -
-3
-4
-3
- -
-5
-5
-4
-6
-3
-3
-2
-4
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
107.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-0.69
- -
- -
- -
- -
-1,660.41
-849.27
-446.74
-1,151.52
-210.11
-19.59
Profit Margin (%)
- -
- -
- -
1
- -
- -
2
2
-1
1
- -
1
-1
-2
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
1
- -
- -
1
2
-1
1
- -
-2
-4
-5
-7
-6
-7
Total Equity
- -
- -
- -
- -
- -
- -
-3.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
0.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.34
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
65
Market Capitalization
6
9
7

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
1
2
Payables & Accruals
1
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
699.47%
132.56%
-13.55%
Free Cash Flow
-172.93%
-125.7%
-43.93%
Net Income, GAAP
1,800.02%
-3.44%
-81.75%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.04
-0.03
-0.03
- -
-0.13
2022
-0.02
-0.03
-0.03
- -
-0.02
2023
-0.02
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
ALK-Abelló A/S (ALK-B.CO)
LadRx Corporation (LADX)
Impel Pharmaceuticals Inc. (IMPL)
Syros Pharmaceuticals, Inc. (SYRS)
LeonaBio, Inc. (LONA)
Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
Business
RepliCel Life Sciences Inc. (TSXV:RP) develops autologous cell therapies for aesthetic and orthopedic conditions caused by deficits in healthy cells needed for tissue healing and function; its core pipeline includes RCT-01 for chronic tendon repair, RCS-01 for skin rejuvenation from aging or sun damage, and RCH-01 for androgenetic alopecia hair restoration, utilizing cell populations isolated from patients' healthy hair follicles. The company, founded in 2011 and headquartered in Vancouver, British Columbia, Canada, also offers the proprietary DermaPrecise injection device and consumables to enhance administration of its therapies and other injectables; RCT-01 and RCS-01 hold exclusive licenses in Greater China to YOFOTO (China) Health Company, while RepliCel retains rights elsewhere, and DermaPrecise has exclusive dermatology rights in Greater China to YOFOTO and U.S. distribution to MainPointe Pharmaceuticals. In August 2024, RepliCel entered definitive agreements to license its patent rights and sell related assets, know-how, brand, and hardware to 1456390 B.C. Ltd., a company controlled by CEO Andrew Schutte, receiving an 8% royalty on gross profits up to US$2.00 per fully diluted share; shareholders approved the transaction in January 2025, it closed with asset sale and royalty establishment by February 2025, prompting voluntary delisting from TSXV effective February 2025, alongside Class A preferred share conversion into common shares and dividend settlement in November 2024.